Cambridge Healthtech Institute’s Inaugural

Driving Clinical Success in Antibody-Drug Conjugates

Impacting Clinical Outcomes

7 November 2024


Antibody-drug conjugates hold transformative potential for cancer treatment, yet their successful clinical translation demands overcoming unique hurdles. CHI’s Driving Clinical Success in Antibody-Drug Conjugates conference hopes to bring attention to these challenges. From maximising therapeutic window to optimising trial design and toxicity management, speakers will share real-world lessons and strategies on achieving better penetration of ADCs into solid tumours, finding translational models that best predict clinical outcomes, expanding ADC applications beyond oncology, and harnessing the power of combination therapies. This conference brings together the stakeholders in the field to navigate the complexities of ADC development and drive impactful clinical outcomes.

Coverage will include, but is not limited to:

  • Exploring the ADC Clinical Landscape — Challenges in Clinical Development of ADCs
    • Tumour heterogeneity
    • Limited target expression
    • Poor penetration of ADCs into solid tumours
    • Restricted therapeutic window
    • Understanding mechanisms-of-resistance to ADCs
  • Clinical Translation and Lessons Learned
    • Considerations for the design of ADC for clinical development —minimum efficacy dose, MTD, drug-antibody ratio, safety vs. efficacy, accurate dose finding, predicting and managing toxicities, developing biomarker strategies
    • What would you change in your clinical trial design?
    • How to broaden therapeutic window?
    • How to improve efficacy with less toxicity?
    • How to identify the right drug-conjugate and MOA to use?
    • Lack of good translational models to predict clinical outcomes
  • Clinical Trial Design
    • Project FrontRunner—redesigning clinical trials to go after first-line treatment
    • Patient selection, stratification, and prediction
    • Identifying the right patient populations for maximum benefit
    • Designing trials for combination therapies
    • Utilizing basket and umbrella trials for efficient evaluation against multiple tumour types
  • Overcoming Toxicity
    • Finding the optimal balance between efficacy and toxicity
    • Mitigate on-target and off-target toxicities
    • Evaluating toxicity in novel formats
  • Expanding Indications
    • Identifying target antigens in non-oncology diseases
    • Opportunity for immune-modulatory ADCs in autoimmune and inflammatory diseases
  • Combination Strategies
    • Combining ADCs with checkpoint inhibitors, small molecule inhibitors, radiotherapies, etc.
    • Managing overlapping toxicities
    • Optimising dosing schedules 

The deadline for priority consideration is 29 March 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation:

For more details on the conference, please contact:

Mimi Langley
Senior Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-972-5439
Email: mlangley@healthtech.com

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1340
Email: ashleyparsons@healthtech.com